Holen Sie sich die Stockscreener-App
1.24
0.81%
0.01
Handel nachbörslich:
1.28
0.04
+3.23%
Schlusskurs vom Vortag:
$1.23
Offen:
$1.255
24-Stunden-Volumen:
26.24M
Relative Volume:
3.40
Marktkapitalisierung:
$419.77M
Einnahmen:
$4.47M
Nettoeinkommen (Verlust:
$-71.67M
KGV:
-5.3494
EPS:
-0.2318
Netto-Cashflow:
$-59.58M
1W Leistung:
+1.64%
1M Leistung:
-7.46%
6M Leistung:
-13.89%
1J Leistung:
+13.76%
1-Tages-Spanne:
$1.24
$1.32
1-Wochen-Bereich:
$1.16
$1.32
52-Wochen-Spanne:
$0.9029
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.24 | 419.77M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen StockFriday review and biotech sector context - AD HOC NEWS
Ocugen Inc (OCGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc (OCGN) Institutional Confidence - TradingKey
Ocugen Inc (OCGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ocugen Inc (OCGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ocugen Inc (OCGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocugen Inc (OCGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
Ocugen's gene-agnostic eye therapies could reshape late-stage care - MSN
Ocugen, Inc.'s (NASDAQ:OCGN) Profit Outlook - Moomoo
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ: OCGN) shareholders back pay, elect directors and confirm new CMO - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
OCGN: All agenda items, including director elections and compensation votes, were approved - TradingView
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc stock (US67577C1053): pipeline updates keep biotech investors watching - AD HOC NEWS
Ocugen Inc stock (US67577C1053): Short interest jumps as investors weigh biotech pipeline - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
· Analyst Forecast - MLQ.ai
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance - Yahoo Finance
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Why Did OCGN Stock Rise Today? - Stocktwits
Why is Ocugen (OCGN) down 10.7% since last earnings report? - MSN
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report? - Yahoo Finance
Ocugen Consolidates Financial Leadership Under New Accounting Officer - TipRanks
Ocugen (NASDAQ: OCGN) CFO assumes principal accounting role - Stock Titan
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care - Yahoo Finance
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? - TradingView
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028 - Yahoo Finance
Ocugen Inc stock (US67577C1053): conference schedule and pre-market moves in focus - AD HOC NEWS
Ocugen to Participate in Upcoming June Investor and Industry Conferences - The Manila Times
Eye gene therapy for blindness hits stage at three June events - Stock Titan
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Ocugen (OCGN) Slides 2.13% to $1.38 as Biotech Stock Tests Key Support LevelsMoving Average Ribbon - The Legal Advocate
Ocugen stock dips as Q1 losses widen - MSN
Ocugen Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity - Moomoo
OCGN Maintained by Canaccord Genuity -- Price Target Lowered to $11 - GuruFocus
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
Ocugen Is Maintained at Buy by Canaccord Genuity - Moomoo
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):